Jinsy A Andrews1, Carlayne E Jackson2, Terry D Heiman-Patterson3, Paolo Bettica4, Benjamin Rix Brooks5, Erik P Pioro6. 1. Neurological Institute of New York, Columbia University, New York, NY, USA. 2. Health Science Center, The University of Texas, San Antonio, TX, USA. 3. Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. 4. Italfarmaco SpA, Milan, Italy. 5. Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine, Charlotte, NC, USA, and. 6. Neuromuscular Centre, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Abstract
OBJECTIVE: To compare the effect of riluzole on median survival in population studies of patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials. Methods: Two independent PubMed searches were conducted, to identify population studies that reported median survival for ALS patients who were either treated with riluzole or remained riluzole-free. Results: We identified 14 studies that met the inclusion criteria of reporting median survival and an additional study that reported mean survival of both riluzole and riluzole-free patients. Analysis of the 15 studies found that a majority reported increased survival of riluzole vs. riluzole-free patients. In 8 studies, the median survival for patients treated with riluzole was 6-19 months longer compared with patients not treated with riluzole (p < 0.05). Three additional studies reported a clinically meaningful treatment effect (range 3-5.9 months) but did not meet statistical significance. The remaining 4 studies did not show a meaningful treatment effect between riluzole and riluzole-free groups (<3 months), and differences among the groups were not significant. Also, 5 of the studies used multivariate regression analysis to investigate the level of association between treatment with riluzole and survival; these analyses supported the positive effect of riluzole on survival. Conclusions: A majority of population studies that compared riluzole vs. riluzole-free ALS patients found significant differences in median survival between the two groups, ranging from 6 to 19 months. This is substantially longer than the 2- to 3-month survival benefit observed in the pivotal clinical trials of riluzole.
OBJECTIVE: To compare the effect of riluzole on median survival in population studies of patients with amyotrophic lateral sclerosis (ALS) with that observed in clinical trials. Methods: Two independent PubMed searches were conducted, to identify population studies that reported median survival for ALS patients who were either treated with riluzole or remained riluzole-free. Results: We identified 14 studies that met the inclusion criteria of reporting median survival and an additional study that reported mean survival of both riluzole and riluzole-free patients. Analysis of the 15 studies found that a majority reported increased survival of riluzole vs. riluzole-free patients. In 8 studies, the median survival for patients treated with riluzole was 6-19 months longer compared with patients not treated with riluzole (p < 0.05). Three additional studies reported a clinically meaningful treatment effect (range 3-5.9 months) but did not meet statistical significance. The remaining 4 studies did not show a meaningful treatment effect between riluzole and riluzole-free groups (<3 months), and differences among the groups were not significant. Also, 5 of the studies used multivariate regression analysis to investigate the level of association between treatment with riluzole and survival; these analyses supported the positive effect of riluzole on survival. Conclusions: A majority of population studies that compared riluzole vs. riluzole-free ALS patients found significant differences in median survival between the two groups, ranging from 6 to 19 months. This is substantially longer than the 2- to 3-month survival benefit observed in the pivotal clinical trials of riluzole.
Authors: Benjamin Rix Brooks; Terry Heiman-Patterson; Martina Wiedau-Pazos; Shawn Liu; Jeffrey Zhang; Stephen Apple Journal: PLoS One Date: 2022-06-14 Impact factor: 3.752
Authors: Sabrina Paganoni; Suzanne Hendrix; Samuel P Dickson; Newman Knowlton; Eric A Macklin; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret Ayo Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry D Heiman-Patterson; Carlayne E Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina N Fournier; Jonathan D Glass; Kristin M Johnson; Andrea Swenson; Namita A Goyal; Gary L Pattee; Patricia L Andres; Suma Babu; Marianne Chase; Derek Dagostino; Meghan Hall; Gale Kittle; Matthew Eydinov; Michelle McGovern; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Maria E St Pierre; Eric Tustison; Prasha Vigneswaran; Jason Walker; Hong Yu; James Chan; Janet Wittes; Zi-Fan Yu; Joshua Cohen; Justin Klee; Kent Leslie; Rudolph E Tanzi; Walter Gilbert; Patrick D Yeramian; David Schoenfeld; Merit E Cudkowicz Journal: Muscle Nerve Date: 2020-10-30 Impact factor: 3.217
Authors: Ahmed Salem; Carter J Wilson; Benjamin S Rutledge; Allison Dilliott; Sali Farhan; Wing-Yiu Choy; Martin L Duennwald Journal: Front Mol Biosci Date: 2022-01-10
Authors: Fatemeh Zahedipour; Seyede Atefe Hosseini; Neil C Henney; George E Barreto; Amirhossein Sahebkar Journal: Neural Regen Res Date: 2022-08 Impact factor: 5.135
Authors: Sabrina Paganoni; Suzanne Hendrix; Samuel P Dickson; Newman Knowlton; James D Berry; Michael A Elliott; Samuel Maiser; Chafic Karam; James B Caress; Margaret Ayo Owegi; Adam Quick; James Wymer; Stephen A Goutman; Daragh Heitzman; Terry D Heiman-Patterson; Carlayne Jackson; Colin Quinn; Jeffrey D Rothstein; Edward J Kasarskis; Jonathan Katz; Liberty Jenkins; Shafeeq S Ladha; Timothy M Miller; Stephen N Scelsa; Tuan H Vu; Christina Fournier; Kristin M Johnson; Andrea Swenson; Namita Goyal; Gary L Pattee; Suma Babu; Marianne Chase; Derek Dagostino; Meghan Hall; Gale Kittle; Mathew Eydinov; Joseph Ostrow; Lindsay Pothier; Rebecca Randall; Jeremy M Shefner; Alexander V Sherman; Eric Tustison; Prasha Vigneswaran; Hong Yu; Joshua Cohen; Justin Klee; Rudolph Tanzi; Walter Gilbert; Patrick Yeramian; Merit Cudkowicz Journal: J Neurol Neurosurg Psychiatry Date: 2022-05-16 Impact factor: 13.654